Luis Carlos Vesga

Dr. Luis Carlos Vesga

Industrial University of Santander, Bucaramanga, Santander, Colombia
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2020 in Medicinal Chemistry Research
Verified
Journal Article
Closed access
PDF file
CBCristian C. Bernal
Cristian C. Bernal
Luis Carlos VesgaLuis Carlos Vesga
Luis Carlos Vesga
SMStelia Carolina Mendez-Sánchez
Stelia Carolina Mendez-Sánchez
Arnold Rafael Romero BohórquezArnold Rafael Romero Bohórquez
Arnold Rafael Romero Bohórquez

12 April 2021 in ChemMedChem
Verified
Journal Article
Open access
PDF file
Luis Carlos VesgaLuis Carlos Vesga
Luis Carlos Vesga
TKThales Kronenberger
Thales Kronenberger
ATArun Kumar Tonduru
Arun Kumar Tonduru
DKDiogo Henrique Kita
Diogo Henrique Kita
IZIngrid Fatima Zattoni
Ingrid Fatima Zattoni
APAntti Poso
Antti Poso
Multidrug resistance (MDR) is one of the major factors in the failure of many chemotherapy approaches. In cancer cells, MDR is mainly associated with the expression of ABC transporters such as P‐glycoprotein, MRP1 and ABCG2. Despite major efforts to develop new selective and potent inhibitors of ABC drug transporters, no ABCG2‐specific inhibitors for clinical use are yet available. Here, we report the evaluation of sixteen tetrahydroquinoline/4,5‐dihydroisoxazole derivatives as a new class of ABCG2 inhibitors. The affinity of the five best inhibitors was further investigated by the vanadate‐sensitive ATPase assay. Molecular modelling data, proposing a potential binding mode, suggest that they can inhibit the ABCG2 activity by binding on site S1, previously reported as inhibitors binding region, as well targeting site S2, a selective region for substrates, and by specifically interacting with residues Asn436, Gln398, and Leu555. Altogether, this study provided new insights into THQ/4,5‐dihydroisoxazole molecular hybrids, generating great potential for the development of novel most potent ABCG2 inhibitors.

1 January 2022 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
IZIngrid Fatima Zattoni
Ingrid Fatima Zattoni
TKThales Kronenberger
Thales Kronenberger
DKDiogo Henrique Kita
Diogo Henrique Kita
LGLais Danciguer Guanaes
Lais Danciguer Guanaes
MGMatheus Murmel Guimarães
Matheus Murmel Guimarães
GVGlaucio Valdameri
Glaucio Valdameri

14 April 2022 in Scientia Pharmaceutica
Verified
Journal Article
Open access
PDF file
Luis Carlos VesgaLuis Carlos Vesga
Luis Carlos Vesga
CRCamilo A. Ruiz-Hernández
Camilo A. Ruiz-Hernández
JJJeimmy J. Alvarez Jacome
Jeimmy J. Alvarez Jacome
JDJonny Edward Duque
Jonny Edward Duque
BRBladimiro Rincón-Orozco
Bladimiro Rincón-Orozco
SMStelia Mendez
Stelia Mendez
Although there are existing vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), new COVID-19 cases are increasing due to low immunization coverage and the emergence of new variants. For this reason, new drugs to treat and prevent severe COVID-19 are needed. Here, we provide four different FDA-approved drugs against SARS-CoV-2 proteins involved in the entry and replication process, aiming to identify potential drugs to treat COVID-19. We use the main protease (Mpro), the spike glycoprotein (S protein), and RNA-dependent RNA polymerase (RdRp) as protein targets for anti- SARS-CoV-2 drugs. In our constructed database, we selected different drugs against each target (Mpro, S protein, and RdRp) based on their common interactions with relevant residues involved in viral entry at the host cell and replication. Furthermore, their stability inside the binding pocket, as well as their predicted binding-free energy, allow us to provide new insight into the possible drug repurposing of viomycin (interacting with Mpro) due to its interactions with key residues, such as Asn 143, Glu 166, and Gln 189 at the same time as hesperidin (interacting with the S protein) is interacting with residues Tyr 449, Ser 494, and Thr 500, keeping inside the predicted binding pocket, as well as interacting with residues in different variants of concern. Finally, we also suggest nystatin and elvitegravir (interacting with RdRp) as possible drugs due to their stability within the predicted pocket along the simulation and their interaction with key residues, such as Asp 760, Asp 761, and Asp 618. Altogether our results provide new knowledge about the possible mechanism of the inhibition of viomycin, hesperidin, elvitegravir, and nystatin to inhibit the viral life cycle of SARS-CoV-2 and some of its variants of concern (VOC). Additionally, some iodide-based contrast agents were also found to bind the S protein strongly, i.e., iohexol (−58.99 Kcal/mol), iotrolan (−76.19 Kcal/mol), and ioxilan (−62.37 Kcal/mol). Despite the information we report here as the possible strong interaction between these contrast agents and the SARS-CoV-2′s S protein, Mpro, and RdRp, we believe that further investigation, including chemical modifications in their structures, are needed for COVID-19 treatment.

22 March 2022 in Journal of Essential Oil Research
Verified
Journal Article
Closed access
DMDiana Carolina Montagut
Diana Carolina Montagut
YBYenny Bueno
Yenny Bueno
Luis Carlos VesgaLuis Carlos Vesga
Luis Carlos Vesga
ESElena E. Stashenko
Elena E. Stashenko
SMStelia Mendez
Stelia Mendez
Cymbopogon flexuosus is a medicinal plant with various biological activities. Although its essential oil (EO) is widely used, the effect of C. flexuosus EO on mitochondrial bioenergetics has not been completely elucidated. Here, we report the effect of C. flexuosus EO on electron transport through the mitochondrial respiratory chain using isolated mitochondria from liver rats. The EO decreases the oxygen consumption rate up to −20% at 10 ppm, and −17% at 25 ppm using glutamate and succinate, respectively. The C. flexuosus EO inhibits the NADH oxidase (34%), succinate oxidase (53%), succinate dehydrogenase (44%), and cytochrome c oxidase (69%) activities at 10 ppm, which indicates a robust inhibitory effect on the electron transport chain. Our results show the inhibitory effect of C. flexuosus EO on electron transport through complex II and IV and suggest that this EO could be used as a potential drug to treat mitochondrial diseases, including cancer.

24 May 2021 in Insect Molecular Biology
Verified
Journal Article
Closed access
PDF file
Stephanie GamezStephanie Gamez
Stephanie Gamez
Luis Carlos VesgaLuis Carlos Vesga
Luis Carlos Vesga
SMS. C. Mendez‐Sanchez
S. C. Mendez‐Sanchez
OAOmar Akbari
Omar Akbari